UY34949A - ?inactivación viral por caprilato?. - Google Patents

?inactivación viral por caprilato?.

Info

Publication number
UY34949A
UY34949A UY0001034949A UY34949A UY34949A UY 34949 A UY34949 A UY 34949A UY 0001034949 A UY0001034949 A UY 0001034949A UY 34949 A UY34949 A UY 34949A UY 34949 A UY34949 A UY 34949A
Authority
UY
Uruguay
Prior art keywords
caprilato
viral inactivation
caprylate
inactivation
viral
Prior art date
Application number
UY0001034949A
Other languages
English (en)
Inventor
Lebing Wytold
Burns Doug
Roth Nathan
Hotta Joann
Original Assignee
Grifols Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48795471&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY34949(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Grifols Sa filed Critical Grifols Sa
Publication of UY34949A publication Critical patent/UY34949A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
    • A01N37/02—Saturated carboxylic acids or thio analogues thereof; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/06—Inactivation or attenuation by chemical treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20261—Methods of inactivation or attenuation
    • C12N2760/20263—Methods of inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24361—Methods of inactivation or attenuation
    • C12N2770/24363—Methods of inactivation or attenuation by chemical treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Environmental Sciences (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Dentistry (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a procedimientos de inactivación de virus que utilizan caprilato e n soluciones que contienen albúmina.
UY0001034949A 2012-08-09 2013-07-25 ?inactivación viral por caprilato?. UY34949A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261681265P 2012-08-09 2012-08-09

Publications (1)

Publication Number Publication Date
UY34949A true UY34949A (es) 2014-03-31

Family

ID=48795471

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001034949A UY34949A (es) 2012-08-09 2013-07-25 ?inactivación viral por caprilato?.

Country Status (24)

Country Link
US (1) US9023797B2 (es)
EP (1) EP2695620B1 (es)
JP (1) JP5926218B2 (es)
KR (1) KR101798386B1 (es)
CN (1) CN103570823A (es)
AR (1) AR091850A1 (es)
AU (1) AU2013205138B2 (es)
BR (1) BR102013018882A2 (es)
CA (1) CA2822229C (es)
CL (1) CL2013002073A1 (es)
ES (1) ES2590150T3 (es)
HK (1) HK1194679A1 (es)
HU (1) HUE029160T2 (es)
IL (1) IL227638A (es)
MX (1) MX340056B (es)
MY (1) MY161287A (es)
NZ (1) NZ613554A (es)
PL (1) PL2695620T3 (es)
PT (1) PT2695620T (es)
RU (1) RU2633059C2 (es)
SG (1) SG2013056387A (es)
TW (1) TWI560196B (es)
UY (1) UY34949A (es)
ZA (1) ZA201305639B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3131589B1 (en) * 2014-04-15 2023-05-17 Boehringer Ingelheim International GmbH Method and use for continuously inactivating a virus during manufacture of a biological product
ES2857582T3 (es) * 2014-04-30 2021-09-29 Novo Nordisk As Métodos para la purificación de proteínas mediante el uso de ácido caprílico
GB201611365D0 (en) 2016-06-30 2016-08-17 Devenish Nutrition Ltd A composition for use in treating rotavirus infection
CN111973582A (zh) * 2020-06-29 2020-11-24 浙江大学 一种正辛酸或正辛酸钠在杀灭冠状病毒中的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2390074A (en) 1942-02-09 1945-12-04 Research Corp Protein product and process
US2469193A (en) 1942-02-09 1949-05-03 Research Corp Protein fractionation
US2710293A (en) 1953-10-30 1955-06-07 Olin Mathieson Blood fractionation
US2710294A (en) 1953-11-02 1955-06-07 Olin Mathieson Blood fractionation
US4939176A (en) 1988-12-20 1990-07-03 Miles Inc. Viral inactivation process
US5250663A (en) 1990-04-19 1993-10-05 Miles Inc. Preparing essentially monomeric normal human serum albumin
US5440018A (en) 1992-05-20 1995-08-08 The Green Cross Corporation Recombinant human serum albumin, process for producing the same and pharmaceutical preparation containing the same
US5521287A (en) * 1992-05-20 1996-05-28 The Green Cross Corporation Recombinant human serum albumin, process for producing the same and pharmaceutical preparation containing the same
US5561115A (en) * 1994-08-10 1996-10-01 Bayer Corporation Low temperature albumin fractionation using sodium caprylate as a partitioning agent
AUPO410696A0 (en) 1996-12-06 1997-01-09 Csl Limited Inactivation of viruses by incubation with caprylate
US5886154A (en) * 1997-06-20 1999-03-23 Lebing; Wytold R. Chromatographic method for high yield purification and viral inactivation of antibodies
AU3624400A (en) 1999-03-19 2000-10-09 Bayer Corporation Chromatographic albumin process
ATE477810T1 (de) * 2002-02-28 2010-09-15 Nipro Corp Stabilisierte albumin-zubereitungen
DK1654284T3 (da) * 2003-08-12 2009-07-20 Octapharma Ag Fremgangsmåde til fremstilling af en alfa-1-antitrypsinoplösning
WO2005082937A2 (en) * 2004-02-27 2005-09-09 Octapharma Ag A method of providing a purified, virus safe antibody preparation
ES2294976B1 (es) * 2007-11-12 2008-12-16 Grifols, S.A. "procedimiento de obtencion de albumina humana de alta eficacia para su uso en terapia de detoxificacion".

Also Published As

Publication number Publication date
MY161287A (en) 2017-04-14
US9023797B2 (en) 2015-05-05
CN103570823A (zh) 2014-02-12
CL2013002073A1 (es) 2014-02-07
PT2695620T (pt) 2016-07-15
IL227638A (en) 2017-06-29
RU2013134696A (ru) 2015-01-27
HUE029160T2 (hu) 2017-02-28
AR091850A1 (es) 2015-03-04
JP2014034575A (ja) 2014-02-24
HK1194679A1 (zh) 2014-10-24
AU2013205138B2 (en) 2015-06-25
TW201416372A (zh) 2014-05-01
NZ613554A (en) 2015-01-30
US20140163101A1 (en) 2014-06-12
RU2633059C2 (ru) 2017-10-11
JP5926218B2 (ja) 2016-05-25
CA2822229C (en) 2018-10-30
MX340056B (es) 2016-06-22
CA2822229A1 (en) 2014-02-09
EP2695620A1 (en) 2014-02-12
TWI560196B (en) 2016-12-01
SG2013056387A (en) 2014-03-28
EP2695620B1 (en) 2016-06-15
ZA201305639B (en) 2017-08-30
PL2695620T3 (pl) 2016-12-30
MX2013008365A (es) 2014-03-05
BR102013018882A2 (pt) 2014-10-29
ES2590150T3 (es) 2016-11-18
KR20140020746A (ko) 2014-02-19
KR101798386B1 (ko) 2017-11-16
AU2013205138A1 (en) 2014-02-27

Similar Documents

Publication Publication Date Title
CY1124431T1 (el) Συριγγα
BR112015023457A2 (pt) sistemas adesivos cationicamente curáveis/ de cianoacrilato de duas partes
UY34587A (es) Formulaciones estabilizadas que contienen anticuerpos antiang2
UY34570A (es) Combinaciones de compuestos inhibidores de la proteína ns5a en el virus de hepatitis c
UY34780A (es) Vectores virales para el tratamiento de distrofia retiniana
UY34875A (es) Purificación de partículas tipo virus
EA201491811A1 (ru) АНТИ-LgR5 АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ
ECSP15011603A (es) Subunidades de vacunas de inmersión para peces
UY34582A (es) Anticuerpos anti-cxcr3
DE112013001416A5 (de) Flächenlichtquelle
CO6811814A2 (es) Vacuna de virus dengue inactivado
BR112014026634A2 (pt) direcionador
EA201590503A1 (ru) Альфа-1-микроглобулин для применения в лечении заболеваний, связанных с митохондриями
UY34949A (es) ?inactivación viral por caprilato?.
UY34286A (es) Diagnóstico de vacuna mejorado
BR112015017420A2 (pt) recombinação de vírus influenza
CU24112B1 (es) Antígenos vacunales quiméricos contra el virus de la hepatitis c
UY4241Q (es) Mesa
CY1124956T1 (el) Συριγγα
TR201314937A2 (tr) Viral enfeksiyonların tedavisine yönelik bir kompozisyon.
UY4215Q (es) Escudo frontal para motocicletas.
ES2721402T3 (es) Agentes herbicidas que contienen tri-alato
UY4256Q (es) ?motocicleta?.
UY4224Q (es) ?escudo frontal para motocicleta?
TR201111860U (tr) Rozetli bariyer.

Legal Events

Date Code Title Description
110 Patent granted

Effective date: 20221018